- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01639690
ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
A Phase I Clinical Trial for the Treatment of ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
The patient has inherited ß-thalassemia major through the genes. These genes have mistakes in them, so the body cannot make normal red blood cells. Stem cells are made in the bone marrow. They are the earliest form of blood cells.
This study is being done to see if the investigators can make the stem cells produce normal red blood cells and hemoglobin. The investigators do this by collecting the stem cells. The genes with mistakes are removed from the cells. These cells are then treated so they have the corrected gene for making normal hemoglobin. These treated cells are given back to the patient through an injection (shot) in the vein. This is also known as gene transfer. In order for the body to accept these cells, the patient will need to receive a low dose of a drug called busulfan. It is a drug that will prepare the body to receive the new stem cells.
This study will let the investigators know:
- If it is safe to give the patient the treated stem cells
- If the treated stem cells will go into the bone marrow without causing side effects.
Gene transfer has been used for the past five years. It has been successful in treating many blood disorders. At least 20 patients have received the type of treatment that the patient will get on this study. This treatment for B-thalassemia major was developed here at Memorial Sloan Kettering (MSK). It was studied for a long time in the lab before being given to patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects must be 18 years or older
- Subjects may be of either gender or of any ethnic background
- Subjects must have a confirmed diagnosis of ß-thalassemia major and have been enrolled in a hypertransfusion program with a confirmed annual transfusion of ≥100 mL/kg/yr but < 200 mL/kg/yr, AND ≥ 8 transfusions of blood per year over a minimum of two years.
- Patients must NOT have an HLA-matched sibling
- Patients must be off hydroxyurea (HU) or erythropoietin (EPO) treatment for at least three months prior to entry onto the study
- Subjects must have a performance score of Karnofsky ≥70% at the time of entry into the study.
- Subjects must have liver iron value of < 15 mg/g/dry weight Iron quantitation may be performed by imaging such as T2*MRI or by biopsy
- Subjects must have no evidence of cirrhosis** of the liver. Fibrosis of the liver can be tested by Fibroscan (47, 48, 49), or by liver biopsy. These should be performed within approximately a one year period prior to entry onto the study.
- Subjects with an evaluation of cardiac function indicating:
- normal function on MUGA scan (Multiple Gated Acquisition scan) or other methodology.
And
- Patients must have a left ventricular ejection fraction (LVEF) of ≥ 60% and/or T2*MRI cardiac evaluation with T2* ≥20 milliseconds
- Subjects with asymptomatic pulmonary function based on Lung Diffusion Testing DLCO Test DLCO ≥ 50% of predicted (corrected for hemoglobin)
- Subjects with a determination of renal function based on: serum creatinine < than or = to 1.5 mg/dL or if serum creatinine is outside the normal range, then CrCl > 60-ml/min/1.73 m2
- Subjects must have adequate hepatic function based on:
- < 3 x ULN ALT and
- < 2.0 total serum bilirubin (unless secondary to hemolysis)
Patients must be available for follow-up evaluations at 30, 60, 180 days post BMT and yearly thereafter indefinitely.
The possibility of unrelated donor stem cell transplantation will be discussed with patients, and a "preliminary" search for an unrelated donor may be done at the request of the patient. However, the finding of a potential HLA-matched unrelated donor will not exclude the patient from participating into this trial).
- As the inclusion criteria are more specific than the Lucarelli/Pesaro thalassemia pre-transplant classification (Class 1,2 or 3 according to presence or absence of fibrosis, adequate chelation and/or hepatomegaly), the criteria stated above will be used in lieu of the Lucarelli/Pesaro classification.
Exclusion Criteria:
- Active infections including Hepatitis B and Hepatitis C***,
- Active infections including HTLV 1 and 2, and HIV 1 and 2
- Patients with treated HLTV or HIV
- Diabetes Mellitus
- Bone Marrow myelodysplasia and/or chromosomal abnormalities
- Female patient pregnant or breast feeding
- Patients with uncontrolled seizure disorders
- Patients with severe pulmonary hypertension Tricuspid Jet velocity > 2.5 m/sec
Family history of familial cancer syndromes (leukemia, breast, ovarian, colorectal, etc.)
*** Definition of active Hepatitis C include:
- Positive HCV RNA Viral load by quantitative PCR testing Or if Negative HCV RNA viral load BUT on antiviral treatment
- Liver biopsy with pathologic evidence of
- Necrosis and inflammation around the portal areas - piecemeal necrosis or interface hepatitis or necrosis of hepatocytes and focal inflammation in the liver parenchyma.
- Inflammatory cells in the portal areas ("portal inflammation").
- Fibrosis, with early stages being confined to the portal tracts, intermediate stages being expansion of the portal tracts and bridging between portal areas or to the central area, and late stages being frank cirrhosis characterized by architectural disruption of the liver with fibrosis and regeneration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous CD34+ cells transduced with TNS9.3.55
An open label study using a non-myeloablative conditioning regimen of busulfan and 1 or several infusions of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the human ß-globin gene.
|
Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells.
CD34+ cells will be purified and transduced ex vivo.
Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed.
Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning.
Patients will be administered 2-12 x 10^6 transduced CD34+ cells per kg in 1 or several infusions.
A back-up of 2 x 10^6 untransduced CD34+ cells per kg will be preserved for every patient.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
safety
Time Frame: 2 years
|
of transplanted autologous CD34+ hematopoietic cells that are transduced ex vivo with TNS9.3.55 and transplanted in subjects with ß-thalassemia major conditioned with a reduced-intensity non-myeloablative preparative regimen.
|
2 years
|
tolerability
Time Frame: 2 years
|
of transplanted autologous CD34+ hematopoietic cells that are transduced ex vivo with TNS9.3.55 & transplanted in subjects with ß-thalassemia major conditioned with a reduced-intensity non-myeloablative preparative regimen.
monitoring the following: 1.
The occurrence of insertional oncogenesis, which will be investigated by monitoring peripheral blood cell counts & leukocyte clonality using FACS analysis, qPCR for vector.
copy number, LAM-PCR and/or 454 sequencing; 2.The generation of a replication-competent lentivirus (RCL).
3.The safety of a low dose non-myeloablative conditioning regimen
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the level of engraftment
Time Frame: 2 years
|
of the genetically modified autologous CD34+ cells and expression of the transduced ß-globin gene as measured by: Blood for measurement of vector copy number and transgene expression in blood cells at months 1, 2 and 3. - Bone Marrow Samples for evaluation of CFU, BFU-E gene+ colonies and Q-PCR will be tested at month 1. |
2 years
|
The frequency of post transplant palliative transfusions
Time Frame: 2 years
|
The number of red blood cell transfusions after engraftment will be quantitatively evaluated for efficacy purposes.
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andromachi Scaradavou, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
General Publications
- Boulad F, Maggio A, Wang X, Moi P, Acuto S, Kogel F, Takpradit C, Prockop S, Mansilla-Soto J, Cabriolu A, Odak A, Qu J, Thummar K, Du F, Shen L, Raso S, Barone R, Di Maggio R, Pitrolo L, Giambona A, Mingoia M, Everett JK, Hokama P, Roche AM, Cantu VA, Adhikari H, Reddy S, Bouhassira E, Mohandas N, Bushman FD, Riviere I, Sadelain M. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with beta-thalassemia: a phase 1 trial. Nat Med. 2022 Jan;28(1):63-70. doi: 10.1038/s41591-021-01554-9. Epub 2022 Jan 3.
- Boulad F, Wang X, Qu J, Taylor C, Ferro L, Karponi G, Bartido S, Giardina P, Heller G, Prockop SE, Maggio A, Sadelain M, Riviere I. Safe mobilization of CD34+ cells in adults with beta-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood. 2014 Mar 6;123(10):1483-6. doi: 10.1182/blood-2013-06-507178. Epub 2014 Jan 15.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Thalassemia
- beta-Thalassemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Busulfan
Other Study ID Numbers
- 10-164
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Confirmed Diagnosis of ß-thalassemia Major
-
Greater Baltimore Medical CenterWithdrawnCancer | Patients With Clinical and Environmental Risk Factors for Cancer | Patients With a Suspected or Confirmed Diagnosis of CancerUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedMajor Sickle Cell Syndrome of Type SS or Sβ ThalassemiaFrance
-
Zhejiang Cancer HospitalNot yet recruitingHistologically Confirmed Breast Cancer ,Diagnosis of Bone Metastasis
-
Chinese University of Hong KongRecruitingConfirmed Diagnosis of Hepatocellular Carcinoma | Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery | Child's A to C CirrhosisHong Kong
-
University Hospital Inselspital, BerneCentre Hospitalier Universitaire Vaudois; Kantonsspital Aarau; University Children... and other collaboratorsRecruitingConfirmed Diagnosis of Cystic FibrosisSwitzerland
-
SanionaCompletedConfirmed Genetic Diagnosis of Prader-Willi SyndromeCzechia, Hungary
-
National Center for Research Resources (NCRR)University of California, Los AngelesCompletedThrombocytopenia | Inborn Errors of Metabolism | Metachromatic Leukodystrophy | Fanconi's Anemia | Thalassemia Major | Pure Red-Cell AplasiaUnited States
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsEnrolling by invitationPrimary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditionsUnited States
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaboratorsRecruitingMitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditionsUnited States, Australia
Clinical Trials on Autologous CD34+ cells transduced with TNS9.3.55
-
Great Ormond Street Hospital for Children NHS Foundation...Recruiting
-
National Institute of Allergy and Infectious Diseases...Enrolling by invitationChronic Granulomatous Disease | p47 | Autosomal RecessiveUnited States
-
GenethonActive, not recruitingWiskott-Aldrich SyndromeUnited Kingdom, France
-
National Institute of Allergy and Infectious Diseases...CompletedSevere Combined ImmunodeficiencyUnited States
-
University of ManchesterUniversity College, London; Manchester University NHS Foundation Trust; Orchard... and other collaboratorsActive, not recruitingMucopolysaccharidosis Type IIIAUnited Kingdom
-
GenethonInstitute of Child Health; Great Ormond Street Hospital for Children NHS Foundation...Completed
-
GenethonHôpital Necker-Enfants MaladesCompleted
-
Great Ormond Street Hospital for Children NHS Foundation...UnknownX-linked Severe Combined ImmunodeficiencyUnited Kingdom
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedPancytopenia | Fanconi's AnemiaUnited States
-
Great Ormond Street Hospital for Children NHS Foundation...RecruitingSevere Combined Immunodeficiency, X-LinkedUnited Kingdom